Table 5.
Summary of costs in the total CDI/rCDI cohorts and the matched CDI/rCDI cohorts
| Before matching | After matching | Before matching | After matching | |||||
|---|---|---|---|---|---|---|---|---|
| Non-CDI | CDI | Non-CDI | CDI | Non-rCDI | rCDI | Non-rCDI | rCDI | |
| Hospitalisation, n | 5 982 231 | 11 823 | 11 461 | 11 607 | 10 464 | 1359 | 1096 | 1320 |
| Medical expenditure (JPY) | ||||||||
| Median (IQR) | 634 967 (370,930, 1,196,608) | 1 962 582 (1,081,847, 3,576,287) | 1 891 891 (1,052,184, 3,344,203) | 1 941 227 (1,076,655, 3,484,586) | 1 808 902 (1,010,982, 3,266,417) | 3 475 730 (2,230,054, 5,951,861) | 3 210 105 (2,014,354, 5,367,351) | 3 426 872 (2,192,061, 5,785,769) |
| Mean (s.d.) | 990 426 (1 247 496) | 3 170 660 (4 142 315) | 2 745 418 (3 064 840) | 2 993 468 (3 544 578) | 2 912 329 (3 888 042) | 5 159 751 (5 331 983) | 4 788 687 (5 275 456) | 5 104 966 (5 347 836) |
| Range | 0–836 403 985 | 7040–91 703 212 | 0–84 164 129 | 7040–64 651 534 | 7040–91 703 212 | 369 918–69 105 695 | 248 603–67 463 837 | 369 918–69 105 695 |
| During entire stay | During residual stay | During entire stay | During residual stay | |||||
| Excess medical expenditure (JPY) | ||||||||
| Median (IQR) | 1 327 615 (710,917, 2,379,678) | 130 296 ( −417,399, 749,960) | 1 666 828 (1,219,072, 2,685,444) | 81 054 ( −1,064,060, 1,139,728) | ||||
| Mean (95% CI) | 2 180 234 (2,105,552, 2,254,915) | 232 163 (175,838, 288,487) | 2 247 423 (1,954,086, 2,540,760) | −54 484 ( −298,220, 189,252) | ||||
| Excess medical expenditure (USD) | ||||||||
| Median (IQR) | 12 069 (6,463, 21,633) | 1185 ( −3,795, 6818) | 15 153 (11,082, 24,413) | 737 ( −9,673, 10,361) | ||||
| Mean (95% CI) | 19 820 (19,141, 20,499) | 2111 (1,599, 2623) | 20 431 (17,764, 23,098) | −495 ( −2,711, 1720) | ||||
CDI, Clostridioides (Clostridium) difficile infection; rCDI, recurrent CDI; JYP, Japanese Yen; IQR, interquartile range; CI, confidence interval; USD, United States Dollar (conversion rate USD 1 = JPY 110).